Literature DB >> 30996791

SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent.

Chiara Borsari1, Nuno Santarem2, Sara Macedo2, María Dolores Jiménez-Antón3, Juan J Torrado3, Ana Isabel Olías-Molero3, María J Corral3, Annalisa Tait1, Stefania Ferrari1, Luca Costantino1, Rosaria Luciani1, Glauco Ponterini1, Sheraz Gul4, Maria Kuzikov4, Bernhard Ellinger4, Birte Behrens4, Jeanette Reinshagen4, José María Alunda3, Anabela Cordeiro-da-Silva2,5, Maria Paola Costi1.   

Abstract

Chemical modulation of the flavonol 2-(benzo[d][1,3]dioxol-5-yl)-chromen-4-one (1), a promising anti-Trypanosomatid agent previously identified, was evaluated through a phenotypic screening approach. Herein, we have performed structure-activity relationship studies around hit compound 1. The pivaloyl derivative (13) showed significant anti-T. brucei activity (EC50 = 1.1 μM) together with a selectivity index higher than 92. The early in vitro ADME-tox properties (cytotoxicity, mitochondrial toxicity, cytochrome P450 and hERG inhibition) were determined for compound 1 and its derivatives, and these led to the identification of some liabilities. The 1,3-benzodioxole moiety in the presented compounds confers better in vivo pharmacokinetic properties than those of classical flavonols. Further studies using different delivery systems could lead to an increase of compound blood levels.

Entities:  

Year:  2019        PMID: 30996791      PMCID: PMC6466517          DOI: 10.1021/acsmedchemlett.8b00565

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

1.  Improvement in solubility and dissolution rate of flavonoids by complexation with beta-cyclodextrin.

Authors:  Silvana Tommasini; Daniela Raneri; Rita Ficarra; Maria Luisa Calabrò; Rosanna Stancanelli; Paola Ficarra
Journal:  J Pharm Biomed Anal       Date:  2004-04-16       Impact factor: 3.935

2.  Antitrypanosomal and antileishmanial activities of flavonoids and their analogues: in vitro, in vivo, structure-activity relationship, and quantitative structure-activity relationship studies.

Authors:  Deniz Tasdemir; Marcel Kaiser; Reto Brun; Vanessa Yardley; Thomas J Schmidt; Fatma Tosun; Peter Rüedi
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

3.  Three-dimensional quantitative structure-activity relationship studies on UGT1A9-mediated 3-O-glucuronidation of natural flavonols using a pharmacophore-based comparative molecular field analysis model.

Authors:  Baojian Wu; John Kenneth Morrow; Rashim Singh; Shuxing Zhang; Ming Hu
Journal:  J Pharmacol Exp Ther       Date:  2010-11-10       Impact factor: 4.030

4.  The leishmanicidal flavonols quercetin and quercitrin target Leishmania (Leishmania) amazonensis arginase.

Authors:  Edson Roberto da Silva; Claudia do Carmo Maquiaveli; Prislaine Pupolin Magalhães
Journal:  Exp Parasitol       Date:  2012-02-01       Impact factor: 2.011

Review 5.  Oral drug therapy for multiple neglected tropical diseases: a systematic review.

Authors:  Madhuri Reddy; Sudeep S Gill; Sunila R Kalkar; Wei Wu; Peter J Anderson; Paula A Rochon
Journal:  JAMA       Date:  2007-10-24       Impact factor: 56.272

6.  Potent inhibitor scaffold against Trypanosoma cruzi trans-sialidase.

Authors:  Shingo Arioka; Masahiro Sakagami; Rie Uematsu; Hiroto Yamaguchi; Hiroko Togame; Hiroshi Takemoto; Hiroshi Hinou; Shin-Ichiro Nishimura
Journal:  Bioorg Med Chem       Date:  2010-01-06       Impact factor: 3.641

7.  Optimization of anti-Trypanosoma cruzi oxadiazoles leads to identification of compounds with efficacy in infected mice.

Authors:  José Maurício dos Santos Filho; Diogo Rodrigo M Moreira; Carlos Alberto de Simone; Rafaela Salgado Ferreira; James H McKerrow; Cássio Santana Meira; Elisalva Teixeira Guimarães; Milena Botelho Pereira Soares
Journal:  Bioorg Med Chem       Date:  2012-08-31       Impact factor: 3.641

8.  DDB treatment of patients with chronic hepatitis.

Authors:  Roman Huber; Birgit Hockenjos; Hubert E Blum
Journal:  Hepatology       Date:  2004-06       Impact factor: 17.425

Review 9.  Trypanosomatid parasites causing neglected diseases.

Authors:  K Nussbaum; J Honek; C M C v C Cadmus; T Efferth
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 10.  Parasite-driven pathogenesis in Trypanosoma brucei infections.

Authors:  L J Morrison
Journal:  Parasite Immunol       Date:  2011-08       Impact factor: 2.280

View more
  1 in total

1.  A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection.

Authors:  Bernhard Ellinger; Denisa Bojkova; Andrea Zaliani; Jindrich Cinatl; Carsten Claussen; Sandra Westhaus; Oliver Keminer; Jeanette Reinshagen; Maria Kuzikov; Markus Wolf; Gerd Geisslinger; Philip Gribbon; Sandra Ciesek
Journal:  Sci Data       Date:  2021-02-26       Impact factor: 6.444

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.